Home

Caren Deardorf

CIK 1871152 · Chief Commercial Officer · last filed 2026-06-22

Caren Deardorf is a Chief Commercial Officer who has filed 15 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for CRNX, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$42.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.86M

Companies

2

Total Filings

15

Lifetime Open-Market Net

-$42.0K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRNX Director 22,225 $83.85 $1.86M $0 7 2026-06-22
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Chief Commercial Officer 1,235 $11.19 $13.8K -$42.0K 8 2022-12-02

Recent Filings

15 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-22 CRNX Grant (A) +5,925 $0 EDGAR
2025-06-13 CRNX Grant (A) +6,900 $0 EDGAR
2024-06-11 CRNX Grant (A) +3,400 $0 EDGAR
2023-06-21 CRNX Grant (A) +6,000 $0 EDGAR
2022-12-02 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) +3,000 $2.8K EDGAR
2022-08-01 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) — $0 EDGAR
2022-06-21 CRNX Grant (A) — $0 EDGAR
2022-06-06 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) +3,000 $3.0K EDGAR
2022-05-19 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) — $0 EDGAR
2022-04-04 CRNX Grant (A) — $0 EDGAR
Showing 1–10 of 15
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.